"EX01A00: Other medical or psychiatric condition incl. recent (within past year) or active suicidal ideation/behavior/lab abnormality that may increase the risk of study participation;
EX02A00: Known infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV);
EX02A06: Phase 1 & 2 only: Known infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV);
EX03A00: History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s);
EX04A00: Receipt of medications intended to prevent COVID-19;
EX05A00: Stages 1 and 2 only:  Previous clinical or microbiological diagnosis of COVID-19;
EX05A05: Previous clinical or microbiological diagnosis of COVID-19;
EX05A07: Previous clinical (based on COVID-19 symptoms/signs alone if no SARS-CoV-2 NAAT result) or microbiological (based on COVID-19 symptoms/signs and positive SARS-CoV-2 NAAT result) diagnosis of COVID-19;
EX06A00: Sentinel participants in Stage 1 only: Individuals at high risk for severe COVID-19;
EX06A01: Sentinel participants in Stage 1 only: Individuals at high risk for severe COVID-19 (full details in protocol).;
EX06A05: Phase 1 only: Individuals at high risk for severe COVID-19 (full details in protocol);
EX07A00: Sentinel participants in Stage 1 only: Individuals currently working in occupations with high risk of exposure to SARS-CoV-2 (eg, healthcare worker, emergency response personnel);
EX07A05: Phase 1 only: Individuals currently working in occupations with high risk of exposure to SARS-CoV-2 (eg, healthcare worker, emergency response personnel);
EX08A00: Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination;
EX09A00: Individuals with a history of autoimmune disease or an active autoimmune disease requiring therapeutic intervention;
EX09A04: Sentinel participants in Stage 1 only: Individuals with a history of autoimmune disease or an active autoimmune disease requiring therapeutic intervention;
EX09A05: Phase 1 only: Individuals with a history of autoimmune disease or an active autoimmune disease requiring therapeutic intervention;
EX10A00: Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection;
EX11A00: Women who are pregnant or breastfeeding;
EX12A00: Previous vaccination with any coronavirus vaccine;
EX13A00: Individuals who receive immunosuppressive therapy, such as cytotoxic agents or systemic corticosteroids. Inhaled/nebulized, Intra-articular, intrabursal, or topical corticosteroids are permitted;
EX13A01: Subjects who receive immunosuppressive therapy, such as cytotoxic agents or systemic corticosteroids;
EX14A00: Receipt of blood/plasma products or immunoglobulin, from 60 days before study intervention administration or planned receipt throughout the study;
EX15A00: Participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation;
EX16A00: Previous participation in other studies involving study intervention containing lipid nanoparticles;
EX17A00: Sentinel participants in Stage 1 only: Positive serological test for SARS-CoV-2 IgM and/or IgG antibodies at the screening visit;
EX17A05: Phase 1 only: Positive serological test for SARS-CoV-2 IgM and/or IgG antibodies at the screening visit;
EX18A00: Sentinel participants in Stage 1 only: Screening hematology/blood chemistry lab >=Grade 1 abnormality. Except Bilirubin, other stable Grade1 abnormalities may be considered eligible by Investigator;
EX18A05: Phase 1 only: Screening hematology/blood chemistry lab >=Grade 1 abnormality. Except Bilirubin, other stable Grade1 abnormalities may be considered eligible by Investigator;
EX19A00: Sentinel participants in Stage 1 only: Positive test for HIV, hepatitis B surface antigen (HBsAg), hepatitis B core antibodies (HBc Abs), or hepatitis C virus antibodies (HCV Abs) at screening visit;
EX19A05: Phase 1 only: Positive test for HIV, hepatitis B surface antigen (HBsAg), hepatitis B core antibodies (HBc Abs), or hepatitis C virus antibodies (HCV Abs) at screening visit;
EX20A00: Sentinel participants in Stage 1 only: SARS-CoV-2 NAAT-positive nasal swab within 24 hours before receipt of study intervention;
EX20A05: Phase 1 only: SARS-CoV-2 NAAT-positive nasal swab within 24 hours before receipt of study intervention;
EX21A00: Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members;
EX21A06: Investigator site staff or Pfizer/BioNTech employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members;
EX22A01: Sentinel participants in Stage 1 only: Regular receipt of inhaled/nebulized corticosteroids;
EX22A05: Phase 1 only: Regular receipt of inhaled/nebulized corticosteroids;
IN01A00: Male or female participants between the ages of 18 and 55 years, inclusive, 65 and 85 years, inclusive, or 18 and 85 years, inclusive, at randomization (dependent upon study stage);
IN01A05: Male or female participants between the ages of 18 and 55 years, inclusive, 65 and 85 years, inclusive, or 18 and 85 years, inclusive, at randomization (dependent upon study phase);
IN01A06: Male or female participants between the ages of 18 and 55 years, inclusive, and 65 and 85 years, inclusive (Phase 1), or >= 16 years (Phase 2/3), at randomization;
IN01A07: Male or female participants between 18 and 55 years inclusive and 65 and 85 years inclusive (Phase 1) or >= 12 years (Phase 2/3) at randomization. Participants <18 years cannot be enrolled in EU;
IN02A00: Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures;
IN03A00: Healthy participants who are determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for inclusion in the study;
IN03A05: Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study;
IN03A06: Healthy participants, determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for the study. Specific criteria apply for HIV/HCV/HBV;
IN04A00: Capable of giving personal signed informed consent, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol;
IN04A07: Capable of giving personal signed informed consent/have parent/legal guardian capable of giving signed informed consent, which includes compliance with requirements, restrictions in ICD and protocol;
IN05A05: Participants who, in the judgment of the investigator, are at risk for acquiring COVID-19;
IN05A06: Phase 2/3 only: Participants who, in the judgment of the investigator, are at higher risk for acquiring COVID-19"
